SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 11, 2003
Indevus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
000-18728 |
04-3047911 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) |
(IRS Employer Identification Number) |
One Ledgemont Center
99 Hayden Avenue
Lexington, Ma 02421-7966
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(781-861-8444)
Item 5. Other Events and Regulation FD Disclosure.
On July 11, 2003, Indevus Pharmaceuticals, Inc., issued a press release announcing the pricing of its offering of $60 million of convertible senior notes due 2008 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Press Release is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits.
| 99.1 | Press Release of the Registrant dated July 11, 2003. |
This Current Report on Form 8-K and the exhibit hereto contain forward-looking statements that involve risks and uncertainties that could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company’s filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under “Risk Factors” and elsewhere, and include, but are not limited to: dependence on the success of trospium; the early stage of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products; risks associated with contractual arrangements; dependence on third parties for manufacturing and marketing; competition; need for additional funds and corporate partners; history of operating losses and expectation of future losses; product liability; risks relating to the Redux-related litigation; limited patents and other proprietary rights; dependence on market exclusivity; valuation of our common stock; risks related to repayment of debts; risks related to increased leverage; and other risks.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INDEVUS PHARMACEUTICALS, INC. | ||||||||
| Dated: July 14, 2003 |
By: | /s/ Glenn L. Cooper | ||||||
| Glenn L. Cooper, M.D. President, Chief Executive Officer and Chairman | ||||||||
3